TransCode Therapeutics CEO Letter to Shareholders
July 05, 2023 07:00 ET
|
TransCode Therapeutics, Inc.
BOSTON, July 05, 2023 (GLOBE NEWSWIRE) -- Dear TransCode Therapeutics Shareholders, I want to express the optimism that permeates the management, board, and staff of TransCode as we navigate the...
TransCode Therapeutics Announces Publication of New Data Supporting the Use of TTX-MC138 for the Treatment of Metastatic Breast Cancer
June 22, 2023 07:00 ET
|
TransCode Therapeutics, Inc.
BOSTON, June 22, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, announced today...
TransCode Therapeutics Announces Closing of $7 Million Public Offering
June 09, 2023 16:05 ET
|
TransCode Therapeutics, Inc.
BOSTON, June 09, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics,...
TransCode Therapeutics Announces Pricing of $7 Million Public Offering
June 06, 2023 17:29 ET
|
TransCode Therapeutics, Inc.
BOSTON, June 06, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics,...
TransCode Therapeutics Reports Positive Preclinical Results with its Lead Candidate, TTX-MC138, in Glioblastoma
June 06, 2023 16:01 ET
|
TransCode Therapeutics, Inc.
BOSTON, June 06, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a leading clinical-stage oncology company committed to using its proprietary delivery system platform to defeat...
TransCode Therapeutics Announces 1-for-20 Reverse Stock Split
May 22, 2023 07:00 ET
|
TransCode Therapeutics, Inc.
BOSTON, May 22, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) (“TransCode” or the “Company”), the RNA Oncology Company™ committed to more effectively treating cancer using RNA...
TransCode Therapeutics Announces IRB Approval for FDA Cleared First-In-Human Clinical Trial
April 27, 2023 07:00 ET
|
TransCode Therapeutics, Inc.
BOSTON, April 27, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a leading clinical-stage oncology company committed to using its proprietary delivery system platform to...
TransCode Therapeutics Announces Strategic Expansion of its Product Portfolio
April 26, 2023 08:00 ET
|
TransCode Therapeutics, Inc.
BOSTON, April 26, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a leading clinical-stage oncology company committed to using its proprietary platform delivery system to...
TransCode Therapeutics Announces Equity Investment from White Lion Capital to Help Fund Development of TTX-MC138 for Treatment of Glioblastomas
April 14, 2023 07:00 ET
|
TransCode Therapeutics, Inc.
BOSTON, April 14, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) (“TransCode” or the “Company”), the RNA Oncology Company™ committed to more effectively treating cancer using...
TransCode Therapeutics to present at AACR Annual Meeting 2023
April 06, 2023 07:00 ET
|
TransCode Therapeutics, Inc.
BOSTON, April 06, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today...